Early and Maintained Treat-to-Target Response with Ixekizumab up to 5 Years in Moderate-to-Severe Psoriasis
Analysis of the UNCOVER-3 Study.
Armstrong A, Merola JF, Chughtai R, Fotiou K, Ngantcha M, Sabatino S, Megna M, Man X, Honma M, Carrascosa JM, Pinter A
Journal of the American Academy of DermatologyIn the feed 16 Sep 2026, published online 16 Sep 2026, issue 2026 Sep 16, added to PubMed 16 Sep 2026
Topics: Psoriasis
Abstract
PubMed has no abstract for this paper, as is usual for research letters, correspondence and editorials. The publisher’s page has the full paper.
PMID 42749063 · DOI 10.1016/j.jaad.2026.09.040